Absci is trading 5.38% lower at $9.15 on October 13, 2026, with no clear company-specific catalyst for the decline. - The company announced it will report third-quarter results on November 12; the announcement does not identify a new business catalyst. - The decline follows two consecutive down sessions, including a 4.82% drop on October 12 after a sharp October 9 gain. Biotech-sector weakness may be contributing, but the sector’s 2.01% decline—and broad-market weakness—does not establish the cause.